Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ ADXS opened at $0.03 on Tuesday. The stock’s 50-day simple moving average is $0.03 and its two-hundred day simple moving average is $0.05. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49. The firm has a market capitalization of $1.15 million, a P/E ratio of 0.00 and a beta of 1.62.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.